http://www.bing.com:80/search?q=Encoded+Files+NotepadSearch resultshttp://www.bing.com:80/s/a/rsslogo.gifhttp://www.bing.com:80/search?q=Encoded+Files+NotepadCopyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.https://encoded.com/Translating Next-Generation Science Into Transformative Gene Therapies Learn About Our ProgramsThu, 09 Apr 2026 05:23:00 GMThttps://encoded.com/news/News & Events Press Releases March 25, 2026 Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome January 12, 2026 Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome January ...Tue, 07 Apr 2026 06:01:00 GMThttps://encoded.com/press-releases/encoded-therapeutics-announces-fda-alignment-initiation-of-pivotal-study-and-asgct-presidential-symposium-presentation-of-etx101-in-dravet-syndrome/Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome FDA alignment achieved on pivotal study design supporting a planned Biologics License Application (BLA) submission 30-patient pivotal study initiated, evaluating seizure reduction and neurodevelopmental outcomes in children aged 6 months to <4 ...Wed, 08 Apr 2026 08:59:00 GMThttps://encoded.com/programs/clinical-studies/Data from observational studies and clinical trials, which depend on volunteer participants, form the foundation of regulatory authorities’ decisions to approve new therapies for broader use.Wed, 08 Apr 2026 02:25:00 GMThttps://encoded.com/about/Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual orientation, religion, age or disability – is one of our biggest strengths as an organization.Wed, 08 Apr 2026 20:05:00 GMThttps://encoded.com/contact/Contact Directory Patients Community and Clinical Trials patientadvocacy@encoded.com Healthcare Providers medinfo@encoded.com Media communications@encoded.com Finance/Accounting ap@encoded.com Partnering partnering@encoded.com Careers careers@encoded.com General Information info@encoded.comWed, 08 Apr 2026 05:46:00 GMThttps://encoded.com/press-releases/encoded-therapeutics-presents-preclinical-data-across-its-gene-therapy-portfolio-at-the-27th-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct/Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Four presentations highlight expansion of the company’s CNS pipeline and vector engineering platform Preclinical data presented supports potential to advance programs in Angelman Syndrome and Lennox-Gastaut Syndrome Proof-of ...Mon, 06 Apr 2026 23:42:00 GMThttps://encoded.com/press-releases/encoded-therapeutics-announces-u-s-fda-breakthrough-therapy-designation-granted-to-etx101-for-the-treatment-of-dravet-syndrome/Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome – Designation recognizes the potential of ETX101 to address a serious condition with high unmet need – SOUTH SAN FRANCISCO, Calif. — January 12, 2026 — Encoded Therapeutics, Inc. (“Encoded”), a clinical-stage biotechnology company developing precision ...Wed, 08 Apr 2026 18:17:00 GMThttps://encoded.com/press-releases/encoded-therapeutics-reports-clinical-progress-of-etx101-gene-therapy-for-dravet-syndrome-recaps-2024-corporate-achievements-and-provides-2025-outlook/Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook POLARIS program, launched in 2024 to evaluate ETX101 for SCN1A+ Dravet syndrome, is ongoing. Expect to complete dosing and share preliminary safety and efficacy data in 2H25. ETX201 gene therapy clinical candidate for Angelman syndrome advanced ...Tue, 07 Apr 2026 05:18:00 GMThttps://encoded.com/programs/Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on pediatric central nervous system (CNS) disorders.Wed, 08 Apr 2026 03:30:00 GMT